Several biopharmaceutical companies continue to undergo restructuring to optimize focus amid challenging market conditions. Rocket Pharmaceuticals cut 30% of staff while narrowing its gene therapy pipeline. Generate:Biomedicines and Tessera Therapeutics also reduced headcount to realign priorities. Galapagos adjusted strategies including potential sale of its cell therapy business after abandoning planned split. AstraZeneca appointed Cristian Massacesi as its Chief Medical Officer, arriving from AstraZeneca’s Alexion unit. Ikena and Inmagene merged with Kristin Yarema appointed CEO. These moves reflect a broader trend of consolidation and leadership shifts to enhance innovation and operational agility.